---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-002410"
form_type: "8-K"
ticker: "RDGL"
cik: "0001449349"
company_name: "VIVOS INC"
filed_at: "2022-01-27T23:59:59+00:00"
generated_at: "2026-06-27T14:55:12.710366+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vivos 2021 recap: first equine IsoPet therapy, FDA pre-sub for RadioGel IDE, production improved 3x

## Summary
- University of Missouri performed first equine IsoPet therapy; excellent outcome confirmed after monitoring.
- Pre-submission meeting with FDA for RadioGel IDE; used rapid breakthrough review; revised IDE to be submitted after biocompatibility tests.
- Polymer production time reduced and output increased by factor of three; contaminants reduced below FDA guidelines.
- New provisional patent filed covering improved hydrogel, other isotopes, and anti-circumvention techniques.
- Capital structure in excellent shape: no toxic debt or derivatives; all SEC filings timely.

## SEC filing metadata
- accession: 0001493152-22-002410
- form_type: 8-K
- ticker: RDGL
- cik: 0001449349
- company_name: VIVOS INC
- filed_at: 2022-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1449349/000149315222002410/0001493152-22-002410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1449349/000149315222002410/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-002410
- JSON: https://secwatch.observer/filing/0001493152-22-002410.json
- Plain text: https://secwatch.observer/filing/0001493152-22-002410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.